Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Melanoma, Circulating Tumor Cells, Metastatic Melanoma, Diagnosis
Interventions: Cytophone; Device
Lead sponsor: Cytoastra; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Heart Disease, Blocked Arteries, Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis
Interventions: MESENDO, placebo; Biological · Other
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Interventions: Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy, Melphalan; Biological · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Congenital Heart Disease, SRV Dependent
Interventions: Autologous mononuclear cells; Biological
Lead sponsor: Timothy J Nelson, MD, PhD; Other
Eligibility: 2 Years to 5 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more

Conditions: Prostate Cancer
Interventions: engineered autologous T cells, cyclophosphamide; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Airway Obstruction Upper, Tonsillectomy, Adenoidectomy Surgery, Hypertrophy
Interventions: Irreversible Electroporation; Device
Lead sponsor: ENTire Medical Ltd.; Industry
Eligibility: 3 Years to 12 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Denver, Colorado • Dallas, Texas

Conditions: Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions: Bone marrow concentration device, Placebo procedure (sham); Device · Procedure
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 21 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 25
States / cities: Little Rock, Arkansas • Sacramento, California • Miami, Florida + 20 more

Conditions: Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, Burkitts Lymphoma, T Cell Lymphomas, Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia
Interventions: cellular immunotherapy; Biological
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Lack of Keratinized Gingiva
Interventions: L-PRF (Leucocyte- platelet rich fibrin), H-PRF (Horizontal -platelet rich fibrin), Surgical stent; Biological · Device
Lead sponsor: Abdo Y Ismail; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Liver Metastases, Non-small Cell Lung Cancer
Interventions: Liver SBRT, Pembrolizumab; Radiation · Drug
Lead sponsor: VA Ann Arbor Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy; Radiation · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Facet Joints; Degeneration, Back Pain, Facet Joint Pain
Interventions: Alocyte low dose, Alocyte medium dose, Alocyte high dose; Drug
Lead sponsor: Alimorad Farshchian; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Kidney Transplant Rejection
Interventions: Retrospective Cohort Enrollment, Prospective Cohort Enrollment; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Type 1 Diabetes
Interventions: Insulin, Asp(B28)-, Glucagon, Placebo; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non Small Cell Lung Cancer
Interventions: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: New York, New York

Conditions: Neuroblastoma
Interventions: Dinutuximab, NK Cells, Lenalidomide; Drug · Biological
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: Up to 30 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 8 more

Conditions: Refractory Depression, Anxiety Disorders, Neurodegenerative Diseases
Interventions: Exosomes; Other
Lead sponsor: Neurological Associates of West Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Spinal Cord Injury
Interventions: Autologous bone marrow-derived mesenchymal stem cells.; Biological
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, External Beam Radiation Therapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy, image-guided radiation therapy, tomotherapy; Other · Radiation
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Anemia, Thalassemia
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Age-Related Macular Degeneration
Interventions: OpRegen; Biological
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 3
States / cities: San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Malignant Glioma
Interventions: D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery); Drug
Lead sponsor: Darell Bigner; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

In Vivo Liquid Biopsy of Melanoma (Cytophone)

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD

Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

Pediatric Adeno-Tonsillar Hypertrophy Treatment Post-Approval Study

Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)

Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma

The Clinical Impact of L-PRF, H-PRF or the Use of Surgical Stent on Palatal Donor Site Healing.

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias

Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain

Bone Marrow for Hemoglobinopathy Research

Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration

D2C7-IT With Atezolizumab for Recurrent Gliomas